Telomir Pharmaceuticals Inc. has announced new preclinical research results showing that its lead compound, Telomir-1, selectively kills aggressive triple-negative breast cancer (TNBC) cells in laboratory studies. The findings reveal that Telomir-1 disrupts cellular energy pathways and mitochondrial function, leading to cancer cell death through iron-dependent mechanisms. When iron was reintroduced, the cancer cells recovered, confirming the compound's activity is closely linked to cellular iron regulation. The company stated that these results provide new insight into Telomir-1's mechanism of action, which appears to target epigenetic changes driving cancer aggressiveness and therapy resistance. Telomir Pharmaceuticals plans to expand research to additional cancer types and conduct animal studies as it prepares for an Investigational New Drug (IND) submission. The announcement did not specify if or when the results will be presented at a scientific meeting or published.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-017422), on October 08, 2025, and is solely responsible for the information contained therein.
Comments